Stuttgart
11.09.26 | 21:56
0,774 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,775 | 0,799 | 12.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.07. | VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis' mission | - | Euronext | ||
| 22.07. | VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum.63 | 846 | Dow Jones News | DJ VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum.63
VALBIOTIS SA
VALBIOTIS... ► Artikel lesen | |
| 26.06. | VALBIOTIS SA: Valbiotis announces the success of its capital increase of EUR10.2M | 1.057 | Dow Jones News | DJ VALBIOTIS SA: Valbiotis announces the success of its capital increase of EUR10.2M
VALBIOTIS SA
VALBIOTIS SA: Valbiotis announces the success of its capital increase of EUR10.2M
26-Jun-2026... ► Artikel lesen | |
| 09.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | 856 | Xetra Newsboard | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| 08.06. | VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of EUR10.2M secured by commitments amounting to 76.6% | 995 | Dow Jones News | DJ VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of EUR10.2M secured by commitments amounting to 76.6%
VALBIOTIS SA
VALBIOTIS SA: Valbiotis... ► Artikel lesen | |
| 27.05. | VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice | 1.006 | Dow Jones News | DJ VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice
VALBIOTIS SA
VALBIOTIS SA: Monacolins... ► Artikel lesen | |
| 17.04. | VALBIOTIS SA: General Meeting of April 17, 2026: All Resolutions Approved | 618 | Dow Jones News | DJ VALBIOTIS SA: General Meeting of April 17, 2026: All Resolutions Approved
VALBIOTIS SA
VALBIOTIS SA: General Meeting of April 17, 2026: All Resolutions Approved
17-Apr-2026 / 17:40 CET/CEST... ► Artikel lesen | |
| 02.03. | VALBIOTIS SA: 2025 Financial Results | 931 | Dow Jones News | DJ VALBIOTIS SA: 2025 Financial Results
VALBIOTIS SA
VALBIOTIS SA: 2025 Financial Results
02-March-2026 / 17:56 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The... ► Artikel lesen | |
| VALBIOTIS Aktie jetzt für 0€ handeln | |||||
| 27.01. | VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4 | 871 | Dow Jones News | DJ VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
VALBIOTIS SA
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in... ► Artikel lesen | |
| 08.12.25 | VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD) | 706 | Dow Jones News | DJ VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
VALBIOTIS SA
VALBIOTIS SA: Valbiotis... ► Artikel lesen | |
| 17.11.25 | VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia | 1.040 | Dow Jones News | DJ Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
VALBIOTIS SA
Valbiotis announces a major strategic agreement... ► Artikel lesen | |
| 09.10.25 | VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap | 1.026 | Dow Jones News | DJ VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 17,550 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TANGO THERAPEUTICS | 23,780 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,870 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| VERA THERAPEUTICS | 35,090 | +0,11 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| QIAGEN | 36,525 | -0,25 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,230 | +0,11 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,450 | +0,11 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 79,31 | 0,00 % | Jefferies erhöht Kursziel für Tarsus Pharmaceuticals nach Prognoseanhebung | ||
| ARCUTIS BIOTHERAPEUTICS | 23,880 | -0,02 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 15,890 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 24,570 | 0,00 % | Arcus Biosciences: Casdatifan-Strategie auf der Cantor Global Healthcare Conference im Fokus | ||
| IMMUNOVANT | 37,330 | -0,08 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,545 | 0,00 % | Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors | Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026... ► Artikel lesen | |
| MODERNA | 124,98 | +0,68 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen |
Das Unternehmen VALBIOTIS SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,774 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALBIOTIS SA finden Sie auf Wallstreet Online.